Education and Training for Clinicians and Beyond
Live Last read · last published · next check
Saves to your Listen queue, to pick up on another day or another device.
Perimenopause is one of the least-researched transitions in women's health. Some women are already microdosing San Pedro to get through it. Deva Collective's founder on why that experience deserves to be studied, not dismissed. The post Why Perimenopause Belongs in Psychedelic Research appeared first on Psychedelics Today .
What happens when a psychedelic experience continues causing problems long after the trip ends? Emory researchers Josh Lipson and Roman Palitsky discuss psychedelic harms, HPPD, spiritual crisis, adverse events, and the Post-Psychedelic Challenges Study. The post Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study appeared first on Psychedelics…
In this week’s Psychedelic Policy Briefing, Investigative Journalist Jack Gorsline digs into the details of four major federal-level developments over the last 7 days. First up, the Department of Veterans Affairs launched a five-site psilocybin trial, and the drug it runs on belongs to a company preparing an application for approval. On capitol hill, the […] The post Weekly Psychedelic Policy…
MAPS co-executive director Ismail Lourido Ali on what the April 2026 executive order, the Texas and Colorado funding fights, and Gabon's new iboga decree mean for who gets access to ibogaine and who benefits from it. The post Ibogaine’s Moment Has Arrived. Are We Ready to Meet It? appeared first on Psychedelics Today .
An Emory study is recruiting 800 people who faced post-psychedelic challenges, to learn what recovery actually takes. The post The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science appeared first on Psychedelics Today .
Broken glassware from Sasha Shulgin’s historic laboratory is being transformed into art. Megan Bowers and Mikayla Hellwich join Joe Moore to discuss the project, MDMA history, DanceSafe, drug checking, prohibition, and cognitive liberty. The post Megan Bowers & Mikayla Hellwich: MDMA History, Harm Reduction, and the Problem With Prohibition appeared first on Psychedelics Today .
The House attached psychedelic amendments to the FY2027 defense bill, VA Secretary Doug Collins promoted the agency's 20 active trials, and Louisiana began spending opioid settlement money on psychedelic research, with the state claiming 20 percent of profits on anything that comes out of it. The post Weekly Psychedelic Policy Briefing – August 2, 2026 appeared first on Psychedelics Today .
Mareesa Stertz returns to discuss how Sphinx Gate is evolving beyond Burning Man into a portable rite of passage. She and Joe explore storytelling, embodiment, psychedelic community, self-trust, and becoming more human in the age of AI. The post Mareesa Stertz – Sphinx Gate Beyond Burning Man: Psychedelic Healing Without Psychedelics appeared first on Psychedelics Today .
Nine of twelve veterans with severe, treatment-resistant PTSD no longer met diagnostic criteria a month after two doses of psilocybin. The trial was designed to test safety, not efficacy, and the most interesting result showed up before anyone took a capsule. The post Psilocybin Trial in Veterans With Treatment-Resistant PTSD Reports 75% Remission at One Month appeared first on Psychedelics Today…
The House voted to extend the Pentagon's psychedelic research program through 2033, then blocked a Right to Try expansion that would have let doctors administer Schedule I drugs to patients with life-threatening conditions. Also this week: signs the FDA may let Resilient Pharmaceuticals resubmit its MDMA application without new trials, two competing pilot program bills advancing in Massachusetts,…
